Ivan Foeldvari
Overview
Explore the profile of Ivan Foeldvari including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
157
Citations
3210
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Foeldvari I, Torok K, Furtado E Silva J, Denton C, Henes J, Horvei P, et al.
Expert Rev Clin Immunol
. 2025 Mar;
PMID: 40056160
Introduction: Autologous stem cell transplantation (ASCT) and cellular therapies (CTs) are emerging therapeutic options for both adult and juvenile-onset systemic sclerosis (jSSc) patients. However, most efficacy data are derived from...
2.
Solebo A, Foeldvari I
Pediatr Rheumatol Online J
. 2025 Jan;
23(1):4.
PMID: 39833902
Childhood blindness significantly impacts development, education, employment, and mental health, creating burden for families and society. Between 8% and 30% of children with Juvenile Idiopathic Arthritis (JIA) develop a potentially...
3.
Sander L, Foeldvari I, Glaser D, Klotsche J, Stier R, Roldan J
J Scleroderma Relat Disord
. 2024 Nov;
:23971983241241099.
PMID: 39552942
Objectives: The objective of this study was to evaluate the effect of autologous fat grafting in patients with juvenile localized scleroderma with facial involvement. Methods: We retrospectively studied patients with...
4.
Foeldvari I, Branton S, Li S, Rosser F, Torok K
J Scleroderma Relat Disord
. 2024 Nov;
:23971983241293297.
PMID: 39544894
Objective: Juvenile-onset systemic sclerosis (jSSc) is a rare and life-threatening disease with no formal studies evaluating the indications for, access to, or benefits of autologous stem cell transplantation (ASCT). As...
5.
Brunner H, Shmagel A, Horneff G, Foeldvari I, Anton J, Ramanan A, et al.
Arthritis Care Res (Hoboken)
. 2024 Nov;
PMID: 39542836
Objective: This work aimed to evaluate the pharmacokinetics, efficacy, and safety of upadacitinib, an oral selective JAK inhibitor, in pediatric patients with polyarticular-course juvenile idiopathic arthritis (pcJIA). Methods: In an...
6.
Milatz F, Pedersen M, Klotsche J, Liedmann I, Niewerth M, Hospach A, et al.
Pediatr Rheumatol Online J
. 2024 Oct;
22(1):93.
PMID: 39434096
Background: Regular physical activity (PA) has been proven to help prevent non-communicable diseases and is beneficial for disease management in chronically ill populations. Physical inactivity and recreational screen-based media (SBM)...
7.
Vojinovic J, Foeldvari I, Dehoorne J, Panaviene V, Susic G, Horneff G, et al.
Rheumatol Ther
. 2024 Sep;
11(6):1437-1440.
PMID: 39264536
This is a summary of the original article 'Ten-year safety and clinical benefit from open label etanercept treatment in children and young adults with juvenile idiopathic arthritis'. Juvenile idiopathic arthritis...
8.
Haney H, Klotsche J, Niewerth M, Hansmann S, Erbis G, Reiser C, et al.
J Rheumatol
. 2024 Sep;
51(10):1048.
PMID: 39227058
No abstract available.
9.
Brunner H, Schulert G, Sproles A, Thornton S, Cornejo G, Anton J, et al.
Arthritis Res Ther
. 2024 Aug;
26(1):154.
PMID: 39217348
No abstract available.
10.
Haney H, Klotsche J, Niewerth M, Hansmann S, Erbis G, Reiser C, et al.
J Rheumatol
. 2024 Aug;
51(10):1023-1032.
PMID: 39089824
Objective: The aim of this study was to develop and psychometrically validate a self-report instrument to assess (1) competencies, (2) needs, and (3) satisfaction among youth transitioning from pediatric to...